00824nam a2200241 i 450099100363654970753620020503202332.0000505s1927 it ||| | ita b10535068-39ule_instEXGIL124357ExLBiblioteca Interfacoltàita616.852Cardona, Filippo469817La nevrastenia :nevrosi d'astenia e nevrosi depressiva /Filippo CarbonaraFirenze :Sansoni,1927228 p.Nevrosi.b1053506802-04-1427-06-02991003636549707536LE002 Ps. II E 1712002000556141le002-E0.00-no 00000.i1061441227-06-02Nevrastenia217654UNISALENTOle00201-01-00ma -itait 3104387nam 2200625 a 450 991079184160332120230725021051.00-309-16157-61-282-78754-397866127875460-309-15655-6(CKB)2560000000067684(EBL)3378669(SSID)ssj0000417460(PQKBManifestationID)11290802(PQKBTitleCode)TC0000417460(PQKBWorkID)10361701(PQKB)10274707(MiAaPQ)EBC3378669(Au-PeEL)EBL3378669(CaPaEBR)ebr10420228(CaONFJC)MIL278754(OCoLC)923282191(EXLCZ)99256000000006768420101105d2010 uy 0engurcn|||||||||txtccrExtending the spectrum of precompetitive collaboration in oncology research[electronic resource] workshop summary /Margie Patlak, Sharyl J. Nass and Erin Balogh, rapporteurs ; National Cancer Policy Forum, Board on Health Care Services, Institute of Medicine of the National AcademiesWashington, D.C. National Academies Press20101 online resource (113 p.)Description based upon print version of record.0-309-15654-8 Includes bibliographical references.""Front Matter""; ""Reviewers""; ""Contents""; ""Boxes, Figures, and Tables""; ""Workshop Summary""; ""Acronyms""; ""Glossary""; ""Appendix A: Workshop Agenda""; ""Appendix B: Polling Results"""Despite spending more time and money in developing novel therapeutics, the success rate for new pharmacologic treatments has been poor. Although the research and development expenditures have grown 13 percent each year since 1970 (a 50-fold increase), the number of new drugs approved annually is no greater now than it was 50 years ago. Over the past decade, skyrocketing costs and the complexity of the scientific knowledge upon which to develop new agents have provided incentives for alternative approaches to drug development, if we are to continue to improve clinical care and reduce mortality. These challenges create opportunities for improved collaboration between industry, academia, government, and philanthropic organizations at each stage in new drug development, marketing, and implementation. Perhaps the most appropriate initial step in addressing the need for collaboration is to consider more precompetitive relationships that allow sharing of scientific information to foster drug development.While these collaborative relationships in basic and preclinical research on drug targets and the early stages of clinical testing are acknowledged to be potentially important drivers for innovation and more rapid marketing of new agents, they also raise a number of concerns that must be addressed. For example, acknowledgment of academic productivity and independence and economic competitiveness must be considered and these challenges managed to foster a culture of collaboration. At the same time, regulatory issues, the need for standardization, and intellectual property concerns must be confronted if the current models for drug development are to be refined to encourage robust participation in precompetitive collaborations. Recognizing the growing importance of precompetitive collaborations in oncology drug development, as well as the challenges these innovative collaborations pose, the National Cancer Policy Forum of the Institute of Medicine held a workshop on February 9 and 10, 2010. This book is a summary of the workshop proceedings."--Publisher's description.OncologyResearchCongressesOncologyResearch616.994Patlak Margie1476477Patlak Margie1476477Nass Sharyl J857626Balogh Erin1089066National Cancer Policy Forum (U.S.)Institute of Medicine (U.S.).Board on Health Care Services.MiAaPQMiAaPQMiAaPQBOOK9910791841603321Extending the spectrum of precompetitive collaboration in oncology research3691153UNINA02996nam 2200697Ia 450 991077708150332120200520144314.01-84755-310-9(CKB)1000000000001208(EBL)1185269(SSID)ssj0000277672(PQKBManifestationID)11195532(PQKBTitleCode)TC0000277672(PQKBWorkID)10241165(PQKB)10930588(SSID)ssj0001682848(PQKBManifestationID)16508139(PQKBTitleCode)TC0001682848(PQKBWorkID)15037047(PQKB)11734765(MiAaPQ)EBC1185269(Au-PeEL)EBL1185269(CaPaEBR)ebr5007005(CaONFJC)MIL871800(OCoLC)843640859(PPN)198468202(EXLCZ)99100000000000120819941208d2001 uy 0engur|n|---|||||txtccrA review of the recent literature published during 1998[electronic resource] monosaccharides, disaccharides, and specific oligosaccharides /senior reporter, R.J. Ferrier ; reporters, R. Blattner ... [et al.]London Royal Society of Chemistryc20011 online resource (414 p.)A Specialist periodical reportCarbohydrate chemistry. ;v.32Includes references and index.0-85404-228-8 CC001032; CC032001; CC032002; CC032003; CC032004; CC032005; CC032006; CC032007; CC032008; CC032009; CC032010; CC032011; CC032012; CC032013; CC032014; CC032015; CC032016; CC032017; CC032018; CC032019; CC032020; CC032021; CC032022; CC032023; CC032024Carbohydrate Chemistry provides review coverage of all publications relevant to the chemistry of monosaccharides and oligosaccharides in a given year. The amount of research in this field appearing in the organic chemical literature is increasing because of the enhanced importance of the subject, especially in areas of medicinal chemistry and biology. In no part of the field is this more apparent than in the synthesis of oligosaccharides required by scientists working in glycobiology. Clycomedicinal chemistry and its reliance on carbohydrate synthesis is now very well established, for example,Specialist periodical report.CarbohydratesDisaccharidesMonosaccharidesOligosaccharidesCarbohydrates.Disaccharides.Monosaccharides.Oligosaccharides.547.78Blattner R1529301Ferrier Robert J1529302MiAaPQMiAaPQMiAaPQBOOK9910777081503321A review of the recent literature published during 19983773439UNINA01685nam 2200385Ia 450 99638746450331620221108093329.0(CKB)4940000000082108(EEBO)2240938801(OCoLC)ocm15666654e(OCoLC)15666654(EXLCZ)99494000000008210819870511d1679 uy |engurbn#|||a|bb|The history of the reformation of the Church of EnglandThe first part[electronic resource] of the progress made in it during the reign of K. Henry the VIII /by Gilbert BurnetLondon Printed by T.H. for Richard Chiswell ...MDCLXXIX [1679][18], 376, [2], 368, [4] p., [7] leaves of plates ill., portsIn two parts. Each part has special t.p. ans separate pagination."A collection of records and original papers, with other instruments referred to in the former history": p. [1]-304 of the third count.Includes engraved portraits, by Robert White, of Henry, Catherine of Aragon, Thomas Wolsey, Thomas Cranmer, Anne Boleyn, Thomas Cromwell, and Thomas More.Reproduction of original in the Cambridge University Library.Includes bibliographical references and indexes.eebo-0021ReformationEnglandReformationBurnet Gilbert1643-1715.193326White Robert1645-1703.845954EAKEAKWaOLNBOOK996387464503316The history of the reformation of the Church of England2359688UNISA